• SEC Filings

OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01 Other Events.

OWC Pharmaceutical Research Corp (“OWC”) and Stenocare A/S (“Stenocare”) have signed a strategic Memorandum of Understanding (MoU) to develop and commercialize new cannabis-based medical products. The new relationship will provide market access to OWC’s technologies and will accelerate Stenocare’s long term strategy to supplement its high quality generic medical cannabis products with differentiated products that are formulated to target specific patient groups suffering from specific conditions.

The companies wish to cooperate in order to jointly develop and promote the sale and distribution of products within Stenocare’s current core markets (Denmark, Ireland) and potentially in new territories to be targeted by Stenocare. The nature of the cooperation is highly synergistic:

About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.